What Manufacturers Need to Know
Seventeen revised draft product-specific guidance documents reflect FDA’s evolving scientific and regulatory approach to generic peptide drug development.
On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17 revised draft product-specific guidances (PSGs) addressing the development of generic peptide drugs, including products used to treat diabetes, obesity, osteoporosis, and macular degeneration.
The revisions reflect advances in analytical science, manufacturing technology, and regulatory experience with complex peptide products. They also provide updated recommendations for manufacturers seeking approval through the abbreviated new drug application (ANDA) pathway.
Unlike many conventional small-molecule drugs, peptide products can present additional challenges involving molecular structure, manufacturing-related impurities, and biological activity. These characteristics can complicate the demonstration that a proposed generic product is equivalent to its reference listed drug.
FDA’s revised guidances address five important areas of generic peptide development.
Five Areas of Regulatory Focus
Peptide Manufacturing and ANDA Eligibility
The revised guidances address the submission of ANDAs for peptides manufactured using recombinant, synthetic, or semisynthetic production methods. These recommendations are particularly relevant when the proposed generic and reference products are manufactured using different technologies.
Innate Immune Response Testing
Peptide products may present immunological concerns that require evaluation. FDA’s updated recommendations address testing related to innate immune responses, an important consideration when assessing product quality and potential safety risks.
Impurity Thresholds
Peptide manufacturing can produce impurities that differ depending on the manufacturing process. The revised guidance documents address impurity thresholds, providing recommendations relevant to impurity characterization, evaluation, and control during generic product development.
Higher-Order Structure Assessment
The three-dimensional structure of a peptide can influence its biological properties. FDA’s recommendations address higher-order structure assessment as part of the scientific evaluation of certain generic peptide products.
Biological Activity Assessment
Demonstrating appropriate biological activity is another important consideration in evaluating peptide products. The revised guidances address biological activity assessments that may contribute to demonstrating equivalence between proposed generic products and their reference drugs.
Together, these five areas illustrate FDA’s emphasis on scientific characterization and evidence-based assessment of complex peptide products. The specific recommendations and supporting evidence will depend on the individual product and its applicable guidance.
FDA Withdraws Earlier Peptide Guidance
Alongside the revised PSGs, FDA withdrew its May 2021 guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, stating that it no longer reflects the agency’s current scientific thinking.
FDA also indicated plans to revise that guidance in 2026.
The withdrawal is particularly relevant for manufacturers whose development strategies relied on the earlier recommendations. Those manufacturers should review the updated product-specific guidance and evaluate whether changes to their development or submission strategies are appropriate.
Implications for Generic Peptide Developers
The revised draft guidances provide an opportunity for manufacturers to reassess their analytical, manufacturing, and regulatory strategies before submitting an ANDA.
Manufacturers developing affected peptide products should consider whether their existing programs adequately address the applicable recommendations for impurity characterization, structural assessment, biological activity, and immunological evaluation.
The recommendations may also have implications beyond the 17 products specifically identified. FDA encourages developers of other generic peptide products to consult its Office of Generic Drugs through formal meetings or controlled correspondence when these recommendations may be applicable.
Importantly, the revised guidances remain in draft form. Manufacturers should distinguish FDA’s proposed recommendations from finalized guidance and applicable regulatory requirements when making development decisions.
Products Covered by the Revised Draft Guidances
The 17 revised draft PSGs address nine peptide ingredients, several of which have multiple reference listed products.
|
Peptide ingredient |
Reference products |
|
Calcitonin salmon |
Calcimar, Miacalcin |
|
Dasiglucagon hydrochloride |
Zegalogue |
|
Glucagon |
Baqsimi, Glucagon, Gvoke |
|
Liraglutide |
Victoza, Saxenda |
|
Pegcetacoplan |
Syfovre, Empaveli |
|
Semaglutide |
Ozempic, Wegovy |
|
Teriparatide |
Forteo, Teriparatide |
|
Tirzepatide |
Mounjaro, Zepbound |
|
Vosoritide |
Voxzogo |
Manufacturers can review the individual recommendations through FDA’s Product-Specific Guidance Database.
Looking Ahead
FDA’s latest revisions underscore the increasing importance of advanced analytical methods and product-specific scientific evidence in generic peptide development.
For manufacturers, the central consideration is not simply whether a peptide can be produced using a particular manufacturing method, but whether the proposed generic product can be adequately characterized and demonstrated to meet applicable requirements for quality, safety, and effectiveness.
As FDA continues refining its approach to complex generic products, manufacturers that evaluate these expectations early in development will be better positioned to identify regulatory gaps, plan appropriate studies, and prepare scientifically supported submissions.
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
The Wolverine Peptide Stack: What We Know
Promoted for faster healing and injury recovery, two experimental peptides are attracting growing consumer interest despite limited human clinical evidence and unresolved safety questions.The promise sounds almost too good to be true: faster recovery from injuries,...
Hims & Hers Moves Into Selling Unapproved Peptides
Telehealth company's planned expansion illustrates how quickly commercial markets are responding to changes in federal oversight of experimental therapies.Hims & Hers Health plans to begin offering new wellness treatments in November, including an unapproved...
FDA Approves Treatment for Advanced Head and Neck Cancer
Rybrevant Faspro receives accelerated approval following promising clinical trial results in patients with limited treatment options.The U.S. Food and Drug Administration (FDA) announced on November 5, 2026, that it has granted accelerated approval to Rybrevant Faspro...
FDA Approves Voceryq, First Plasmid DNA Immunotherapy
Voceryq offers adults with recurrent respiratory papillomatosis a new treatment approach that targets the underlying viral infection and may reduce the need for repeated surgeries.The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voceryq,...
When Political Priorities and FDA Science Collide
HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...
FDA Moves Toward New Peptide Compounding Policy
FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...
First T-Cell Therapy to Reduce Disease after Cell Transplant
FDA Approves First Regulatory T-Cell Therapy to Reduce Chronic Graft-versus-Host Disease After Stem Cell TransplantThe First Regulatory T (Treg) Cell-Based Immunotherapy The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T (Treg)...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...




